Comments on: Bigtime Biotech Thinkers Steven Burrill and Gary Pisano Agree on Bright Future of Industry, Disagree on How to Build Value http://www.xconomy.com/boston/2009/10/08/bigtime-biotech-thinkers-steven-burrill-and-gary-pisano-agree-on-bright-future-of-industry-disagree-on-how-to-build-value/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 12:29:49 +0000 hourly 1 http://wordpress.org/?v=3.0.4 By: Anthony Tjan: The Art Of The Exit – Uniqs.info | Headline News http://www.xconomy.com/boston/2009/10/08/bigtime-biotech-thinkers-steven-burrill-and-gary-pisano-agree-on-bright-future-of-industry-disagree-on-how-to-build-value/comment-page-1/#comment-88082 Anthony Tjan: The Art Of The Exit – Uniqs.info | Headline News Fri, 23 Oct 2009 16:13:05 +0000 http://www.xconomy.com/?p=45062#comment-88082 [...] Bigtime Biotech Thinkers Steven Burrill and Gary Pisano Agree on Bright Future of Industry, Disagre... [...] [...] Bigtime Biotech Thinkers Steven Burrill and Gary Pisano Agree on Bright Future of Industry, Disagre… [...]

]]> By: gregory simpson http://www.xconomy.com/boston/2009/10/08/bigtime-biotech-thinkers-steven-burrill-and-gary-pisano-agree-on-bright-future-of-industry-disagree-on-how-to-build-value/comment-page-1/#comment-86624 gregory simpson Mon, 12 Oct 2009 17:50:58 +0000 http://www.xconomy.com/?p=45062#comment-86624 I definitely agree that the transition from a new drug to a diagnostically (preventative medicine) driven business model is inevitable. We are already seeing those changes by the investments companies such as Affymetrix are making in disease specific diagnostic gene array platforms. My issue is what new eduction platforms are going to be needed to support this change in Health care strategy? Would venture capital investment in developing training and education models, provide an avenue? Particularly for those companies with compromised cash follows. The fact that there are so few opportunities for the broader community to interact with these advanced technologies, much less understand them, mitigates against the long term viability of the current biotech business model. In addition, since the health insurance platforms will also be changed, providing education solutions at the payer/payee levels will become more of a premium over the next decade. Any comments? I definitely agree that the transition from a new drug to a diagnostically (preventative medicine) driven business model is inevitable. We are already seeing those changes by the investments companies such as Affymetrix are making in disease specific diagnostic gene array platforms.

My issue is what new eduction platforms are going to be needed to support this change in Health care strategy?

Would venture capital investment in developing training and education models, provide an avenue? Particularly for those companies with compromised cash follows.

The fact that there are so few opportunities for the broader community to interact with these advanced technologies, much less understand them, mitigates against the long term viability of the current biotech business model.

In addition, since the health insurance platforms will also be changed, providing education solutions at the payer/payee levels will become more of a premium over the next decade.

Any comments?

]]> By: I Am Biotech: Discover. Share. Discuss. http://www.xconomy.com/boston/2009/10/08/bigtime-biotech-thinkers-steven-burrill-and-gary-pisano-agree-on-bright-future-of-industry-disagree-on-how-to-build-value/comment-page-1/#comment-86620 I Am Biotech: Discover. Share. Discuss. Mon, 12 Oct 2009 16:18:31 +0000 http://www.xconomy.com/?p=45062#comment-86620 [...] LEADERS STEVEN BURRILL & GARY PISANO ON THE FUTURE OF THE INDUSTRY – Xconomy had an interesting piece detailing a segment at MassBio’s Investor Forum last week, which put biotech luminaries [...] [...] LEADERS STEVEN BURRILL & GARY PISANO ON THE FUTURE OF THE INDUSTRY – Xconomy had an interesting piece detailing a segment at MassBio’s Investor Forum last week, which put biotech luminaries [...]

]]> By: Beam Me (and my spit) Up Scotty « CXO Footnotes http://www.xconomy.com/boston/2009/10/08/bigtime-biotech-thinkers-steven-burrill-and-gary-pisano-agree-on-bright-future-of-industry-disagree-on-how-to-build-value/comment-page-1/#comment-86244 Beam Me (and my spit) Up Scotty « CXO Footnotes Fri, 09 Oct 2009 12:36:33 +0000 http://www.xconomy.com/?p=45062#comment-86244 [...] This is not a trivial pursuit, but it will happen over time.  Some think sooner than later.  This week at the MassBio Investors Forum in Boston, Steven Burrill, CEO of Burrill & Company, offered his view of the future: [...] [...] This is not a trivial pursuit, but it will happen over time.  Some think sooner than later.  This week at the MassBio Investors Forum in Boston, Steven Burrill, CEO of Burrill & Company, offered his view of the future: [...]

]]>